

2024

Yonsei Team Science Award Symposium:

Precision Therapeutics for Hearing Loss



| DATE | 4 October (FRI), 2024

| VENUE | NEWILHAN Memorial Hall, Avison BioMedical Research Center (ABMRC),
Yonsei University College of Medicine

REGISTRATION



| | | |
|-------------|---|--|
| 08:40–08:45 | Welcome remarks | Sung Huhn Kim (Director of Won-Sang Lee Institute for Hearing Loss, Korea) |
| 08:45–10:35 | Gene replacement therapy | Chair: Sung Huhn Kim (Yonsei Univ, Korea) |
| 08:45–09:15 | Advances and challenges in gene therapy for hereditary hearing loss | Hidekane Yoshimura (Shinshu Univ, Japan) |
| 09:15–09:45 | Gene therapy for auditory neuropathy | Chen-Chi Wu (Taiwan Nat'l Univ, Taiwan) |
| 09:45–10:15 | Development of inner ear gene therapy as a treatment for Usher syndrome | Wade Chien (Johns Hopkins School of Medicine) |
| 10:15–10:35 | Gene therapy for Pendred syndrome/DFNB4 | Dae-Won Kim (ICM, Korea) |
| 10:35–10:50 | Coffee break | |
| 10:50–12:30 | Gene editing therapy | Chair: Shi Nae Park (Catholic Univ, Korea) |
| 10:50–11:20 | Editing approach to treat genetic hearing loss | Zheng-Yi Chen (Harvard Univ, USA) |
| 11:20–11:50 | Template-independent genome editing for restoration of a DFNB9 mouse model in vivo | Wei Xiong (Chinese Institute for Brain Research, China) |
| 11:50–12:10 | PAM-flexible adenine base editing to rescue hearing loss in a humanized MPZL2 mouse model harboring East Asian founder mutation | Sang-Yeon Lee (Seoul Nat'l Univ, Korea) |
| 12:10–12:30 | <i>In vivo</i> gene editing to ameliorate progressive hearing loss in DFNA2 murine model | Jinsei Jung (Yonsei Univ, Korea) |
| 12:30–12:35 | Photo time | |
| 12:35–14:00 | Lunch | |
| 14:00–15:40 | ASO and Cell therapy | Chair: Un-Kyung Kim (Kyungpook Univ, Korea) |
| 14:00–14:30 | Alternative splicing regulates tip-link stability and auditory function in mice | Zhigang Xu (Shandong Univ, China) |
| 14:30–14:50 | Development of ASO therapeutics for patients with DFNA2 | Heon Yung Gee (Yonsei Univ, Korea) |
| 14:50–15:20 | Hearing restoration: gene therapy or in situ hair cell regeneration? | Zhiyong Liu (Chinese Academy of Sciences, China) |
| 15:20–15:40 | Preclinical study for novel approaches in inner ear drug delivery | Yong Ho Park (Chungnam Nat'l Univ, Korea) |
| 15:40–15:55 | Coffee break | |
| 15:55–17:55 | New drug under clinical trial for treating hearing loss | Chair: Yong Ho Park (Chungnam Nat'l Univ, Korea) |
| 15:55–16:25 | Clinical trial outcome of low dose Sirolimus for DFNB4 and Pendred syndrome | Masato Fujioka (Kitasato Univ, Japan) |
| 16:25–16:45 | Therapeutics for mitochondria-associated hearing loss | Kyu-Yup Lee (Kyungpook Nat'l Univ, Korea) |
| 16:45–17:05 | Preclinical and clinical data of NS101 in noise-induced hearing loss | Jinwoong Bok (Yonsei Univ, Korea) |
| 17:05–17:55 | DB-OTO: an AAV-based Gene Therapy for Children and Infants with Otoferlin-related Hearing Loss | Yoojin Chung, Vassili Valayannopoulos (Regeneron, USA) |
| 17:55–18:00 | Closing remarks | Jinsei Jung (Director of Team Science Award, Korea) |



Team Science Award
YONSEI UNIVERSITY



Won-Sang Lee
Institute for Hearing Loss